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ABSTRACT
Aim: To study the influence of prednisone dose during
the first month after systemic lupus erythematosus (SLE)
diagnosis (prednisone-1) on glucocorticoid burden
during the subsequent 11 months (prednisone-2–12).
Methods: 223 patients from the Registro Español de
Lupus Eritematoso Sistémico inception cohort were
studied. The cumulative dose of prednisone-1 and
prednisone-2–12 were calculated and recoded into a
four-level categorical variable: no prednisone, low dose
(up to 7.5 mg/day), medium dose (up to 30 mg/day)
and high dose (over 30 mg/day). The association
between the cumulative prednisone-1 and prednisone-2–
12 doses was tested. We analysed whether the four-
level prednisone-1 categorical variable was an
independent predictor of an average dose >7.5 mg/day
of prednisone-2–12. Adjusting variables included age,
immunosuppressives, antimalarials, methyl-prednisolone
pulses, lupus nephritis and baseline SLE Disease
Activity Index (SLEDAI).
Results: Within the first month, 113 patients (51%) did
not receive any prednisone, 24 patients (11%) received
average low doses, 46 patients (21%) received medium
doses and 40 patients (18%) received high doses. There
was a strong association between prednisone-1 and
prednisone-2–12 dose categories (p<0.001). The
cumulative prednisone-1 dose was directly associated
with the cumulative prednisone-2–12 dose (p<0.001).
Compared with patients on no prednisone, patients taking
medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or
high-dose prednisone-1 (adjusted OR 10.5, 95% CI
3.8 to 29.17) were more likely to receive prednisone-
2–12 doses of >7.5 mg/day, while patients receiving low-
dose prednisone-1 were not (adjusted OR 1.4, 95% CI
0. 0.38 to 5.2). If the analysis was restricted to the
158 patients with a baseline SLEDAI of ≥6, the model
did not change.
Conclusion: The dose of prednisone during the first
month after the diagnosis of SLE is an independent
predictor of prednisone burden during the following
11 months.
Glucocorticoids constitute one of the main
therapies for systemic lupus erythematosus
(SLE). However, despite their proven efficacy,
oral glucocorticoids are important predictors
of irreversible damage in lupus.1 2 Therefore,
new ways of treating lupus beyond the use of
high-dose oral prednisone are needed.
Registro Español de Lupus Eritematoso
Sistémico (RELES) is the first Spanish multi-
centric inception lupus cohort, a research
project of the Spanish Group of Autoimmune
Diseases within the Spanish Society of
Internal Medicine. The analysis of patterns of
initial therapy in 223 patients enrolled up to
July 2014 has been recently published.3 Our
database offers the opportunity of studying
the influence of prednisone therapy during
the first month after the diagnosis on the
glucocorticoid burden during the subsequent
11 months of follow-up.
METHODS
Patients at the time of SLE diagnosis,
defined as meeting at least four American
College of Rheumatology classification
criteria,4 were included since January 2009.
A total of 32 Internal Medicine Departments
from hospitals all over Spain participated in
this study. All patients signed an informed
consent document at the time of enrolment.
The study protocol was approved by the
Institutional Research Ethics Boards of the
coordinating centre (Hospital Universitario
Cruces) and of all participating centres.
Detailed characteristics of the database
have been recently published.3 Relevant to
this study, every modification of therapy was
entered in the database, so that it was
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possible to calculate the cumulative dose of immunosup-
pressive and immunomodulatory drugs for a given
period of time. For the purposes of this study, the cumu-
lative dose of prednisone at the first month
(prednisone-1) and within the following 11 months
(prednisone-2–12) were calculated and transformed
into average daily doses, expressed in milligram/day.
Such continuous variables were further recoded into a
four-level categorical variable according to the classifica-
tion by Buttgereit et al5: no prednisone, low dose (up to
7.5 mg/day), medium dose (up to 30 mg/day) and high
dose (over 30 mg/day).
Statistical analysis
Descriptive data were generated, using percentages,
means and SDs. This study aimed to find associations
between prednisone-1 and prednisone-2–12. The associ-
ation between the four-level categorical prednisone-1
and prednisone-2–12 variables (no prednisone, low,
medium and high doses) was tested by McNemar’s test.
The association between the cumulative prednisone-1
and prednisone-2–12 doses was tested by linear regres-
sion, adjusted by the use of immunosuppressive drugs,
weeks on antimalarials, methyl-prednisolone pulses,
presence of nephritis and baseline SLE Disease Activity
Index (SLEDAI). We also analysed whether the
four-level prednisone-1 categorical variable was an inde-
pendent predictor of an average dose >7.5 mg/day of
prednisone 2–12. This cut-off point was selected accord-
ing to the published data identifying this dose as the
limit for glucocorticoid-related damage accrual.6 Logistic
regression was used for the analysis, with age at onset,
immunosuppressive drugs, weeks on antimalarials,
methyl-prednisolone pulses, lupus nephritis and baseline
SLEDAI included as independent covariables. In order
to eliminate the bias caused by mild disease, the analysis
was repeated after excluding patients with a baseline
SLEDAI of <6. All the statistical calculations were made
with STATA (V.11.2; STATA, Texas, USA).
RESULTS
A total of 223 patients were included in this study. The
main clinical characteristics of the cohort are shown on
table 1. About 89% of patients were women, 86% were
Caucasians and 21% presented with lupus nephritis.
The mean (SD) SLEDAI score at diagnosis was 9.8 (7.8).
Of note, 158 patients (70%) had a baseline SLEDAI of
≥6. By the end of the first year, the mean (SD) SLEDAI
score had significantly decreased to 4.4 (4.3), p<0.001.
Fifty patients (22%) had accrued any damage by the
end of the first year of follow-up. During this period, no
patients suffered avascular bone necrosis; three patients
suffered vertebral crush fractures, aged 61, 23 and
75 years and having received average prednisone-2–12
doses of 1.8, 18 and 19.6 mg/day, respectively.
Within the first month, 113 patients (51%) did not
receive any prednisone, 24 patients (11%) received
average low doses, 46 patients (21%) received medium
doses and 40 patients (18%) received high doses (table 2).
The use of medium-high doses of prednisone was asso-
ciated with the presence of nephritis (OR 4.1, 95% CI 1.9
to 8.9), thrombocytopenia (OR 4.3, 95% CI 1.7 to 11.3),
anti-DNA antibodies (OR 2.1, 95% CI 1.07 to 4.3)
and SLEDAI score at diagnosis of ≥6 (OR 2.8, 95% CI 1.3
to 6.1).
Table 2 Association between prednisone doses received
during the first and subsequent 11 months of follow-up
after the diagnosis of systemic lupus erythematosus
Prednisone-2–12
Prednisone-1 No Low Medium High
No (n=113) 79 (70%) 20 (18%) 14 (12%) 0 (0%)
Low (n=24) 1 (4%) 19 (79%) 4 (17%) 0 (0%)
Medium
(n=46)
2 (4%) 19 (41%) 25 (54%) 0 (0%)
High (n=40) 0 (0%) 10 (25%) 25 (62%) 5 (13%)
Prednisone-1: average prednisone dose during the first month.
Prednisone-2–12: average prednisone dose during months 2–12.
Table 1 Baseline clinical manifestations in and
treatments received within the first year by 223 patients of
the Registro Español de Lupus Eritematoso Sistémico
(RELES) cohort
N (%)
Clinical manifestations
Malar rash 55 (25%)
Discoid rash 17 (8%)
Subacute cutaneous lupus 29 (13%)
Cutaneous vasculitis 8 (4%)
Arthritis 98 (44%)
Lupus nephritis 47 (21%)
Class I 2 (1%)
Class II 3 (1.5%)
Class III 5 (2%)
Class IV 24 (11%)
Class V 6 (3%)
No biopsy 7 (4%)
Pleuritis 28 (13%)
Pericarditis 25 (11%)
Haemolytic anaemia 19 (9%)
Thrombocytopenia 32 (14%)
Venous thromboembolism 22 (10%)
Stroke 5 (2%)
Treatments
Prednisone 144 (65%)
HCQ 182 (81%)
Pulse methyl-prednisolone 34 (15%)
Any immunosuppressive drug 88 (39%)
Cyclophosphamide 26 (12%)
Azathioprine 32 (14%)
Methotrexate 20 (9%)
Mycophenolate (sodium or mofetil) 42 (19%)
Tacrolimus 1 (0.5%)
HCQ, hydroxychloroquine.
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There was a strong association between prednisone-1
and prednisone-2–12 dose categories (p<0.001, table 2).
Of note, 54% of patients treated with medium doses
during the first month received medium average pred-
nisone 2–12 doses; among those treated initially with
high doses, the proportion of patients receiving average
prednisone doses of >7.5 mg/day increased to 75%.
Likewise, the cumulative prednisone-1 dose during the
first month was directly associated with the cumulative
prednisone-2–12 dose (R2 0.3, p<0.001). This association
remained unchanged after adjusting for age, immunosup-
pressive drugs, antimalarials, methyl-prednisolone pulses,
presence of nephritis and baseline SLEDAI (p<0.001).
Patients taking medium or high doses of prednisone-1
were more likely to be treated with prednisone-2–12
doses of >7.5 mg/day, compared with patients on no
prednisone (OR 8.4, 95% CI 3.7 to 18.8 and OR 21.2,
95% CI 9.8 to 52.6, respectively); on the contrary,
patients receiving low doses during the first month
were not (OR 1.4, 95% CI 0.87 to 4.7). After adjusting
for immunosuppressive drugs, antimalarials, methyl-
prednisolone pulses, presence of nephritis, age and
baseline SLEDAI, the results were similar (table 3). If
the analysis was restricted to the 158 patients with a base-
line SLEDAI of ≥6, the model did not change substan-
tially (table 3). Of note, the use of immunosuppressive
drugs predicted treatment with doses of prednisone of
>7.5 mg/day; however, adding methyl-prednisolone
pulses to the therapeutic scheme reduced the odds of
being treated with medium-high doses of prednisone-2–
12, particularly in patients with a baseline SLEDAI of ≥6
(table 3). On the other hand, antimalarials had no
effect, a fact that could be attributed to the high propor-
tion of patients taking hydroxychloroquine (182/223,
82%), equally distributed in patients with and without
prednisone (12/144, 84% vs 61/79, 77%, respectively,
p=0.2).
DISCUSSION
Early therapy of SLE often relies on glucocorticoids.7 8
In fact, there are not better drugs to achieve a rapid
effect in patients with active disease. However, prolonged
treatment with prednisone is often devastating.
Glucocorticoids therapy is a major predictor of irrevers-
ible damage in SLE, showing a strong relation with com-
plications such as osteonecrosis, osteoporotic fractures,
diabetes, cataracts or cardiovascular disease,1 6 not to
mention the profound physical changes that can exert a
long-lasting impact on the quality of life of young
patients. Treat-to-target recommendations by an inter-
national task force aim for the lowest glucocorticoid
dosage needed to control disease during lupus mainten-
ance treatment.9 Recent data have shown that average
doses of prednisone over 7.5 mg/day during the first
year of disease course significantly increase damage
accrual within 5 years.6 Moreover, data showing similar
efficacy of regimes based on combination therapy
containing lower doses of prednisone have been recently
published, both in patients with10–12 and without lupus
nephritis.13 Thus, maintenance doses of >7.5 mg/day
could and should be avoided.
A recent study of the RELES cohort including these
same 223 patients has revealed that as many as 38% of
the patients were treated with average medium-high
doses of prednisone (ie, >7.5 mg/day) during the first
year after the diagnosis.3 We hypothesised that patters of
glucocorticoid use are potentially dependent on the
treating physician and this fact could be well investigated
in this observational multicentric cohort in which thera-
peutic protocols were not predefined at all.
Our results confirm that, regarding prednisone use,
what physicians did during the first month after the
diagnosis of SLE was predictive of what happened within
the following 11 months. Patients treated with initial low
doses of prednisone were likely to be kept on low doses
during the following months. On the other hand, half of
the patients on initial medium doses received subse-
quent medium-high doses, a proportion that increased
to 75% among those starting on high doses. It could be
Table 3 Adjusted logistic regression model for predictors
of average doses of prednisone >7.5 mg/day during the
months 2–12 of follow-up after systemic lupus
erythematosus (SLE) diagnosis, in the whole cohort and
limited to patients with a baseline SLEDAI of ≥6
OR 95% CI
Whole cohort (n=223)
Prednisone-1
No Reference Reference
Low 1.43 0.38 to 5.3
Medium 5.8 2.3 to 14.3
High 10.8 3.9 to 29.8
Methyl-prednisolone bolus
(yes/no)
0.32 0.10 to 1.02
Immunosuppressive drugs
(yes/no)
2.88 1.21 to 6.8
Weeks on HCQ 1.00 0.99 to 1.00
Baseline SLEDAI 1.07 1.01 to 1.14
Nephritis 1.67 0.53 to 5.1
Age at diagnosis 0.98 0.96 to 1.01
Baseline SLEDAI of ≥6 (n=158)
Prednisone-1
No Reference Reference
Low 1.49 0.29 to 7.5
Medium 4.6 1.65 to 12.9
High 11.4 3.5 to 37.03
Methyl-prednisolone bolus
(yes/no)
0.13 0.03 to 0.57
Immunosuppressive drugs
(yes/no)
2.39 0.85 to 6.6
Weeks on HCQ 1.00 0.99 to 1.00
Baseline SLEDAI 1.06 0.98 to 1.13
Nephritis 3.64 0.96 to 13.8
Age at diagnosis 0.98 0.95 to 1.01
Prednisone-1: average prednisone dose during the first month.
HCQ, hydroxychloroquine; SLEDAI, SLE Disease Activity Index.
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argued that higher initial doses are related with more
severe disease and, thus, with higher needs of subse-
quent intensive therapy. However, this is only a partial
explanation, since the influence of initial glucocorticoid
therapy was independent from the baseline SLEDAI
score and the presence of lupus nephritis, also in those
patients presenting with a SLEDAI of ≥6. Similar to pre-
vious results from the RELES cohort, immunosuppres-
sive use did not result in reduced doses3 of prednisone
while intravenous methyl-prednisolone bolus were related
with lower doses of oral prednisone, particularly in
patients with more active disease at presentation.
The dependence of the therapeutic protocol on the
responsible physician/hospital could be seen as a limita-
tion to this study. However, this heterogeneity in thera-
peutic protocols is actually the key in showing that the
patterns of glucocorticoid use are more doctor-dependent
than based on disease severity. The inception cohort
design, the diagnosis of all patients after 2009 and the
detailed acquisition of data on drug therapy are also
important strengths of this study that make its conclusions
quite solid. Unfortunately, due to the limited follow-up of
1 year, the analysis of the relation between general or
glucocorticoid-related damage accrual and prednisone or
intravenous methyl-prednisolone was premature, accord-
ing to previous studies.6 10 13 This will be hopefully pos-
sible with longer observational periods of our cohort.
Thus, it can be concluded that every effort should be
made to limit oral glucocorticoid use since the very
beginning of SLE course. Methyl-prednisolone bolus
may help achieve rapid remission while reducing the
need for oral prednisone.13 14
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